Item 5. Market for Registrant’s Common Equity
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
Market Information.
Our units, public shares and public warrants are traded on the NYSE under the symbols “SBXD.U”, “SBXD” and “SBXD. WS”, respectively.
Holders
Although there are a larger number of beneficial owners, at March 13, 2025, there was one holder of record of our units, one holder of record of our Class A ordinary shares, one holder of record of our founder shares, one holder of record of our Public Warrants and one holder of record of our private placement warrants.
Dividends
We have not paid any cash dividends on our ordinary shares to date and do not intend to pay cash dividends prior to the completion of our initial business combination. The payment of cash dividends in the future will be dependent upon our revenues and earnings, if any, capital requirements and general financial condition subsequent to completion of our initial business combination. The payment of any cash dividends subsequent to a business combination will be within the discretion of our board of directors at such time. Further, if we incur any indebtedness, our ability to declare dividends may be limited by restrictive covenants we may agree to in connection therewith.
Securities Authorized for Issuance under Equity Compensation Plans
None.
Performance Graph
Not applicable.
68
Table of Contents
Recent Sales of Unregistered Securities; Use of Proceeds from Registered Offerings
Unregistered Sales
On April 18, 2024, we issued 3,450,000 founder shares to our sponsor for $25,000. In May 2024, we effected a share split for which an additional 2,300,000 founder shares were issued and the sponsor now holds 5,750,000 founder shares.
On June 10, 2024, concurrently with the closing of the Initial Public Offering, our sponsor purchased an aggregate of 455,000 private placement units at a price of $10.00 per private placement unit, for an aggregate purchase price of $4,550,000, in a private placement. These issuances were made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act.
No underwriting discounts or commissions were paid with respect to such sales.
Use of Proceeds
Of the proceeds we received from the Initial Public Offering and the exercise of over-allotment option by underwriters as well as the sale of the private placement units, a total of $201,000,000, including $10,300,000 of deferred underwriting commissions and after deducting of the other underwriting commissions and expenses for the Initial Public Offering, was placed in the trust account with Continental Stock Transfer & Trust Company acting as trustee.
There has been no material change in the planned use of proceeds from such use as described in our prospectus filed with the SEC on June 7, 2024 pursuant to Rule 424b(4).
Purchases of Equity Securities by the Issuer and Affiliated Purchasers
None.
ITEM 6. [RESERVED]
69
Table of Contents
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.